Similar articles

• The clinical pharmacology of a hepatoma-specific alkylating agent.

  Curt CA, Cannors TA, Murray-Lyon IM, Tattersall MH. Curt CA, et al. Biochem Pharmacol. 1977 Sep 15;26(18):1715-8. doi: 10.1016/0006-2952(77)90150-2. Biochem Pharmacol. 1977. PMID: 197970 No abstract available.
• [Effects of intra-hepatic arterial injection of mitoxantrone for hepatocellular carcinoma].

  Hiraki S, Nishida M, Maeda Y, Nakashima K, Takao K, Takao T, Oka M, Suzuki T. Hiraki S, et al. Gan To Kagaku Ryoho. 1996 Sep;23(11):1415-8. Gan To Kagaku Ryoho. 1996. PMID: 8854767 Japanese.
• Trial of adriamycin in primary hepatocellular carcinoma.

  Tsega E. Tsega E. Ethiop Med J. 1984 Jan;22(1):55-9. Ethiop Med J. 1984. PMID: 6317377 Clinical Trial. No abstract available.
• [The effect of etoposide (Et) on primary hepatocellular carcinoma].

  Tanaka N, Furusawa A, Shimoda A, Hirai N, Unoura M, Kato Y, Kobayashi K, Izumi R, Matsui O, Hattori N. Tanaka N, et al. Gan To Kagaku Ryoho. 1987 Aug;14(8):2583-5. Gan To Kagaku Ryoho. 1987. PMID: 3039924 Japanese. No abstract available.
• [Treatment of small hepatocellular carcinoma by percutaneous injection of ethanol].

  Livraghi T, Lazzaroni S, Vettori C. Livraghi T, et al. J Radiol. 1992 Jan;73(1):55-7. J Radiol. 1992. PMID: 1312174 French. No abstract available.